Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia Daniel G. GuyGeoffrey L. Uy Acute Myeloid Leukemias (H Erba, Section Editor) 02 October 2018 Pages: 417 - 425
Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies Imo J. AkpanAfaf E. G. OsmanLucy A. Godley Acute Myeloid Leukemias (H Erba, Section Editor) 26 September 2018 Pages: 426 - 434
Chronic Myeloid Leukemia: Beyond BCR-ABL1 Ting ZhouL. Jeffrey MedeirosShimin Hu Molecular Testing and Diagnostics (J Khoury, Section Editor) 29 October 2018 Pages: 435 - 445
Recent Updates on Chronic Myelomonocytic Leukemia Sanam LoghaviJoseph D. Khoury Molecular Testing and Diagnostics (J Khoury, Section Editor) 11 October 2018 Pages: 446 - 454
Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry Franklin FudaWeina Chen Molecular Testing and Diagnostics (J Khoury, Section Editor) 17 November 2018 Pages: 455 - 466
Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria Maria Sanz-De PedroWei WangJoseph D. Khoury Molecular Testing and Diagnostics (J Khoury, Section Editor) 18 October 2018 Pages: 467 - 476
Blastic Plasmacytoid Dendritic Cell Neoplasm Joseph D. Khoury Molecular Testing and Diagnostics (J Khoury, Section Editor) 22 October 2018 Pages: 477 - 483
Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy Jacob S. AppelbaumFilippo Milano CART and Immunotherapy (M Ruella, Section Editor) 02 October 2018 Pages: 484 - 493
Novel Immunotherapies for T Cell Lymphoma and Leukemia Paola GhioneAlison J. MoskowitzMarco Ruella CART and Immunotherapy (M Ruella, Section Editor) 13 October 2018 Pages: 494 - 506
Leveraging Hypomethylating Agents for Better MDS Therapy Terrence J. BradleyJustin M. WattsRonan T. Swords Myelodysplastic Syndromes (M Savona, Section Editor) 28 September 2018 Pages: 507 - 515
Breast Implant-Associated Anaplastic Large Cell Lymphoma P. RastogiA. K. DevaH. Miles Prince T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 22 October 2018 Pages: 516 - 524
Targeted Therapies in CLL: Monotherapy Versus Combination Approaches Maliha KhanTanya Siddiqi Chronic Lymphocytic Leukemias (N Jain, Section Editor) 10 December 2018 Pages: 525 - 533
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma Robert HavardDeborah M. Stephens B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 25 October 2018 Pages: 534 - 542
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma Bei HuRyan JacobsNilanjan Ghosh B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 18 October 2018 Pages: 543 - 554
Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies Helen MaAhmed Sawas B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor) 25 October 2018 Pages: 555 - 569
Online and Social Media Resources for Patients with MDS Nour AbuhadraAziz Nazha Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 10 October 2018 Pages: 570 - 575
Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities Sagar S. PatelNavneet S. Majhail Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 15 October 2018 Pages: 576 - 580
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community Naveen PemmarajuAudun UtengenAndrew A. Lane Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 18 October 2018 Pages: 581 - 587
Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations Bing LiJohn O. MascarenhasRaajit K. Rampal Myeloproliferative Neoplasms (B Stein, Section Editor) 23 October 2018 Pages: 588 - 595
